Hybridoma Technology

Monoclonal antibodies are secreted from hybridoma cells which are created by fusing a collection of short-lived antibody producing B cells with immortal myeloma cells.

Hybridoma technology. These hybrid cells are produced by fusing B-lymphocytes with tumor cell and they are called myeloma cells. The resulting hybrid cells called hybridomas combine the longevity of the myeloma cell with the ability to produce a specific antibody and so are able to produce potentially unlimited amounts of the desired antibody. These antibody producing B-cells are then harvested from the mouse and in turn fused with immortal B cell cancer cells a myeloma to produce a hybrid cell line called a hybridoma which has both the antibody-producing ability.

At the same time it can divide continuously by the quality derived from myeloma cell. Hybridoma technology is the method in which large quantity of identical antibodies are produced which are also known as monoclonal antibodies. Hybridoma technology has long been a remarkable and indispensable platform for generating high-quality monoclonal antibodies mAbs.

Hybridoma-derived mAbs have not only served as powerful tool reagents but also have emerged as the most rapidly expanding class of therapeutic biologics. An antibody producing B- lymphocytes eg. Monoclonal antibodies can be produced in specialized cells through a technique now popularly known as hybridoma technology Hybridoma technology was discovered in 1975 by two scientists Georges Kohler and Cesar Milstein who jointly with Niels Jerne of Denmark now working in Germany were awarded the 1984 Noble prize for physiology and medicine.

This process starts by injecting a mouse with an antigen that provokes an immune response. Being foreign to human the murine antibody is further chimerized via r-DNA technology to reduce its immunogenicity for therapeutic use. Hybridomas are cells formed via fusion between a short-lived antibody-producing B cell and an immortal myeloma cell.

Hybridoma technology is a method for producing large amounts of identical antibodies hence monoclonal antibodies as opposed to the conventional polyclonal antibodies. Each hybridoma constitutively expresses a large amount of one specific mAb and favored hybridoma cell lines can be cryopreserved for long-lasting mAb production. Monoclonal antibodies have a wide variety of clinical and research applications.

By combining the desired qualities of both the cells the technology ensures large antibody production of single specificity. HYBRIDOMA TECHNOLOGY ITS APPLICATION Represent by. A type of white blood cell the B cell produces antibodies that bind to the injected antigen.